DLL3 and breast cancer: The above studies show that, in BC, PDAC, and EOC, high expression of Notch ligands (mainly Jagged1, Jagged2, and Dll3) of tumor cells promotes an immunosuppressive microenvironment in the TME, eventually allowing tumors to tolerate immunotherapy.